6-K filed Jul 27, 2026 at 07:51 ET
AstraZeneca reported H1 2026 Total Revenue of $30.7B (+6% CER) and Core EPS of $5.21 (+11% CER), with strong double-digit growth in Oncology and Rare Disease offset by BioPharmaceuticals headwinds from Farxiga US loss of exclusivity and China VBP. Q2 2026 Reported EPS was essentially flat (+2% actual, -2% CER) as R&D and SG&A spending increased. The company reconfirmed FY 2026 guidance (mid-to-high single-digit revenue growth, low double-digit Core EPS growth) and announced two license deals (Dizal $600M upfront, Sino Biopharma $200M upfront), but the Wainua CARDIO-TTRansform Phase III failure in ATTR-CM is a notable pipeline setback.